Evaluates targeting CD38 with felzartamab in antibody-mediated kidney transplant rejection, suggesting a potential strategy to reduce graft injury.
Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option.
No takes yet. Share an insight, caveat, or question.
Mayer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: